ChiCTR2500110662 版本V1.0 版本创建时间2025/10/19 19:24:01 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2500110662 

最近更新日期:

Date of Last Refreshed on:

2025-10-17 11:54:33 

注册时间:

Date of Registration:

2025-10-17 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

中国骨盆髋臼骨折专病队列研究

Public title:

Chinese Pelvic and Acetabulum Fracture Cohort

注册题目简写:

English Acronym:

研究课题的正式科学名称:

中国骨盆髋臼骨折专病队列研究

Scientific title:

Chinese Pelvic and Acetabulum Fracture Cohort

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

薛沛然 

研究负责人:

陈开放 

Applicant:

Xue Peiran 

Study leader:

Chen Kaifang 

申请注册联系人电话:

Applicant telephone:

+86 27 85726524

研究负责人电话:

Study leader's telephone:

+86 27 85726524

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

XUEPeiran@outlook.com

研究负责人电子邮件:

Study leader's E-mail:

ckf@hust.edu.cn

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

中国湖北省武汉市江汉区解放大道1277号

研究负责人通讯地址:

湖北省武汉市江汉区解放大道1277号

Applicant address:

1277 Jiefang Avenue, Jianghan Distric, Wuhan, Hubei, China

Study leader's address:

1277 Jiefang Avenue, Jianghan Distric, Wuhan, Hubei, China

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

华中科技大学同济医学院附属协和医院

Applicant's institution:

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

研究负责人所在单位:

华中科技大学同济医学院附属协和医院

Affiliation of the Leader:

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

是否获伦理委员会批准:

是/Yes

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

[2025]伦审字(0922)号

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

华中科技大学同济医学院附属协和医院医学伦理委员会

Name of the ethic committee:

Ethics Committee of Union Hospital of Tongji Medical College Huazhong University of Science and Technology

伦理委员会批准日期:

Date of approved by ethic committee:

2025-09-02 00:00:00

伦理委员会联系人:

褚圆圆

Contact Name of the ethic committee:

Chu Yuanyuan

伦理委员会联系地址:

湖北省武汉市江汉区解放大道1277号

Contact Address of the ethic committee:

1277 Jiefang Avenue, Jianghan Distric, Wuhan, Hubei, China

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 27 85726375

伦理委员会联系人邮箱:

Contact email of the ethic committee:

994877373@qq.com

研究实施负责(组长)单位:

华中科技大学同济医学院附属协和医院

Primary sponsor:

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

研究实施负责(组长)单位地址:

湖北省武汉市江汉区解放大道1277号

Primary sponsor's address:

1277 Jiefang Avenue, Jianghan Distric, Wuhan, Hubei, China

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

湖北

市(区县):

Country:

China

Province:

Hubei

City:

单位(医院):

华中科技大学同济医学院附属协和医院

具体地址:

湖北省武汉市江汉区解放大道1277号

Institution
hospital:

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Address:

1277 Jiefang Avenue, Jianghan Distric, Wuhan, Hubei, China

经费或物资来源:

自选课题(自筹)

Source(s) of funding:

Self-funded

Target disease:

Pelvic and acetabular fractures

Target disease code:

研究类型:

观察性研究

Study type:

Observational study

研究所处阶段:

其它 

Study phase:

N/A

研究设计:

队列研究 

Study design:

Cohort study 

研究目的:

骨盆髋臼骨折手术被誉为创伤骨科领域的“皇冠上的明珠”,主要归因于其手术难度大、风险高。骨盆环结构极为不规则,这种不规则性极大地增加了骨折复位和固定的难度。此外,骨盆区域承接了泌尿系统、生殖系统和消化系统,同时下肢的神经血管也在此区域穿行,解剖结构极为复杂,手术风险相对较高。加之该区域血管丰富,术中易出现大出血,导致患者死亡率升高。骨盆髋臼位于人体中心,受到良好保护,一旦发生严重损伤,其危害不容小觑。 针对骨盆髋臼骨折手术存在的解剖结构不规则和内部器官密集等问题,给骨折复位固定带来了极大挑战。具体表现在两个方面:一是复位时入路和手术方式选择困难,传统髂腹股沟入路和KL入路创伤较大,手术时间较长,亟待优化;二是固定困难,由于骨盆结构不规则,缺乏合适的内固定材料,目前全球范围内均相对缺乏针对这种复杂结构的解剖型钢板。若骨折复位良好后,钢板与骨面不贴合,可能导致固定效果不佳,甚至引发再移位。 本研究拟通过回顾既往骨盆髋臼骨折患者的骨折类型、手术入路、手术方式、固定方式和预后情况,以及前瞻性收集骨盆髋臼骨折患者的骨折类型、手术入路、手术方式、固定形式等信息,分析上述因素与预后的关系。  

Objectives of Study:

Pelvic acetabular fractures surgery is regarded as the "crown jewel" in the field of trauma orthopedics, mainly due to its high surgical difficulty and risk. The pelvic ring structure is extremely irregular, which greatly increases the difficulty of fracture reduction and fixation. Moreover, the pelvic region houses the urinary, reproductive, and digestive systems, and the nerves and blood vessels of the lower extremities also pass through this area, making the anatomical structure very complex and increasing the surgical risk. Additionally, the rich blood supply in this area makes major bleeding during surgery more likely, leading to an increased mortality rate. The pelvic acetabulum is located at the center of the human body and is well protected. Once severely injured, its harm cannot be underestimated. The irregular anatomical structure and dense internal organs of the pelvic acetabulum pose significant challenges to fracture reduction and fixation. This is manifested in two aspects: first, it is difficult to choose the approach and surgical method for reduction. Traditional ilioinguinal and KL approaches cause significant trauma and have long operation times, which need to be optimized; second, fixation is difficult. Due to the irregular pelvic structure, there is a lack of suitable internal fixation materials. Currently, there is a global shortage of anatomical plates specifically designed for this complex structure. If the plate does not fit the bone surface well afte

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

1.经X线和(或)CT诊断证明的骨盆髋臼骨折;
2.经骨科医生判断需手术治疗患者;
3.年龄>=18周岁;
4.患者或其授权代理人承诺配合随访及签署知情同意书;

Inclusion criteria

1.Pelvic acetabular fractures diagnosed by X-ray and/or CT.
2.Patients judged by the orthopedic doctor to require surgical treatment;
3.over 18 years old;
4.The patient or their authorized representative agrees to cooperate with the follow-up and to sign the informed consent form.

排除标准:

1.病理性骨盆髋臼骨折;
2.开放性骨盆髋臼骨折;
3.因肿瘤或其他疾病导致预计寿命在12个月内的;
4.末次月经至产后1个月的孕产妇;

Exclusion criteria:

1.Pathological pelvic acetabular fractures;
2.Open pelvic acetabular fracture;
3.Due to tumors or other diseases, the expected lifespan is less than 12 months.
4.Pregnant women from the last menstrual period to one month postpartum;

研究实施时间:

Study execute time:

From 2025-10-31 00:00:00 To 2030-09-30 00:00:00  

征募观察对象时间:

Recruiting time:

From 2025-10-31 00:00:00 To 2030-09-30 00:00:00  

干预措施:

Interventions:

组别:

观察组

样本量:

200

Group:

Observational group

Sample size:

干预措施:

干预措施代码:

Intervention:

None

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

湖北 

市(区县):

 

Country:

China 

Province:

Hubei 

City:

 

单位(医院):

华中科技大学同济医学院附属协和医院 

单位级别:

三级甲等 

Institution
hospital:

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

湖北 

市(区县):

 

Country:

China 

Province:

Hubei 

City:

 

单位(医院):

襄阳市枣阳市第一人民医院 

单位级别:

三级甲等 

Institution
hospital:

Zaoyang first People's Hospital

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

河北 

市(区县):

 

Country:

China 

Province:

Hebei 

City:

 

单位(医院):

河北医科大学第三医院 

单位级别:

三级甲等 

Institution
hospital:

Hebei Medical University Third Hospital

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

湖北 

市(区县):

 

Country:

China 

Province:

Hubei 

City:

 

单位(医院):

随州市中心医院 

单位级别:

三级甲等 

Institution
hospital:

Suizhou Central Hospital

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

广东 

市(区县):

 

Country:

China 

Province:

Guangdong 

City:

 

单位(医院):

南方医科大学第三附属医院 

单位级别:

三级甲等 

Institution
hospital:

The Third Affiliated Hospital of Southern Medical University

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

湖北 

市(区县):

 

Country:

China 

Province:

Hubei 

City:

 

单位(医院):

武汉市中西医结合医院(武汉市第一医院) 

单位级别:

三级甲等 

Institution
hospital:

Traditional Chinese and Western Medicine Hospital of Wuhan Wuhan No1 Hospital

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

湖北 

市(区县):

 

Country:

China 

Province:

Hubei 

City:

 

单位(医院):

华中科技大学同济医学院附属同济医院 

单位级别:

三级甲等 

Institution
hospital:

Tongji Hospital, Tongji Medical College ,Huazhong University of Science and Technology

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

改良Merle d'Aubigné-Postel评分(髋臼亚队列)

指标类型:

主要指标

Outcome:

Modified Merle d'Aubigné-Postel (Acetabulum)

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

ICU停留时间

指标类型:

次要指标

Outcome:

Time in ICU

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

再次手术次数

指标类型:

次要指标

Outcome:

Number of reoperations

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

骨折类型

指标类型:

次要指标

Outcome:

Type of the fracture

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

Majeed评分(骨盆亚队列)

指标类型:

主要指标

Outcome:

Majeed Score (Pelvic Subcohort)

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

手术方式

指标类型:

次要指标

Outcome:

Type of the surgery

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

手术时长

指标类型:

次要指标

Outcome:

Time of the surgery

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

Matta评分

指标类型:

次要指标

Outcome:

Matta score

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

住院时间

指标类型:

次要指标

Outcome:

Time in hospital

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

手术出血量

指标类型:

次要指标

Outcome:

Volume of the bleeding

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

不良事件发生率

指标类型:

次要指标

Outcome:

Incidence of adverse events

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

组织:

Sample Name:

None

Tissue:

人体标本去向

其它  

说明

Fate of sample:

0thers  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age 18 years
最大 Max age years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

Randomization Procedure (please state who generates the random number sequence and by what method):

None

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

不公开/Private

盲法:

Blinding:

None

是否共享原始数据:

IPD sharing

Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

预计在ResMan共享

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

Expected to be shared on ResMan.

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

CRF ;EDC

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

CRF; EDC

数据与安全监察委员会:

Data and Safety Monitoring Committee:

有/Yes

注册人:

Name of Registration:

 2025-10-17 11:54:33